Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The patent portfolio for Ok Nam Park is positioned within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action reported for this entity. This action is being handled by 1 distinct examiner, which indicates the current interaction with the USPTO. For a portfolio of this size, the outcome of the active prosecution phase rests on the decisions of a specific individual.
The prosecution activity is confined to the distinct art unit, reflecting the technical focus of the filings. FIEBIG, RUSSELL G is the busiest examiner for Ok Nam Park, with the busiest examiner pending office action. Since this is the pending action in the portfolio, the examiner's specific interpretation of Biotechnology & Pharmaceuticals standards will be the primary factor in the progress of the portfolio. The data shows the prosecution profile without diversification across different examiners or art units for Ok Nam Park.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911401 | AN ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASE AND THE USE THEREOF | FIEBIG, RUSSELL G | 87d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911401 | AN ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASE AND THE USE THEREOF | FIEBIG, RUSSELL G | 87d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17911401 | AN ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASE AND THE USE THEREOF | FIEBIG, RUSSELL G | 1655 | §101§103§112 | Non-Final OA | 87d overdue | Pending | Sep 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial